Healthcare Services

Global cancer profiling market to reach $25.62B by 2030 at 11.3% CAGR

April 20, 2026April 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Cancer Profiling Market Progress Between 2026 And 2030?

The cancer profiling market has experienced substantial growth in recent years. It is anticipated to expand from $15 billion in 2025 to $16.67 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.1%. The increase observed in previous periods is attributable to factors like a surge in cancer incidence rates, the expansion of molecular diagnostics laboratories, the early integration of genomic testing in oncology, an increase in research-based cancer profiling, and the growing availability of diagnostic platforms.

The cancer profiling market is anticipated to experience significant expansion in the coming years. This market is projected to reach $25.62 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.3%. This expansion during the forecast period can be attributed to several factors, including a heightened demand for precision medicine approaches, the proliferation of companion diagnostics, the broader application of liquid biopsy technologies, increased investments in oncology diagnostics, and the greater incorporation of profiling into standard clinical workflows. Key trends anticipated during this period encompass the wider adoption of ngs-based cancer profiling, an increase in the utilization of comprehensive genomic panels, the growing integration of ai for data interpretation, the expansion of personalized oncology diagnostics, and an intensified focus on early molecular detection.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

Which Primary Drivers Are Impacting The Cancer Profiling Market Growth?

The projected expansion of the cancer profiling market is anticipated to be fueled by the rising occurrence of cancer. Cancer incidence quantifies the new diagnoses within a particular demographic over a defined timeframe. This escalation in cancer cases stems from factors such as increased urbanization, an expanding elderly population, evolving lifestyle choices, and various environmental and genetic influences. Cancer profiling facilitates the detection of distinct molecular or genetic alterations within a tumor, including gene mutations or other modifications in tumor DNA, thereby proving beneficial throughout the cancer treatment process. For example, data from July 2024, provided by the Australian Institute of Health and Welfare, an Australian governmental body, revealed that in 2023, approximately 165,000 Australians received a new cancer diagnosis, translating to more than 450 cases daily, with males accounting for roughly 55% of these new diagnoses. Consequently, the growing prevalence of cancer is a key impetus behind the expansion of the cancer profiling market.

What Are The Different Segment Types In The Cancer Profiling Market Segment Breakdown?

The cancer profiling market covered in this report is segmented –

1) By Technology: Immunoassays, PCR (Polymerized Chain Reaction), NGS (Next-Generation Sequencing), Microarrays, In-Situ Hybridization

2) By Biomarker Type: Genomic Biomarkers, Protein Biomarkers

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancers

4) By Application: Research Applications, Clinical Applications, Diagnostics, Prognostics, Other Applications

Subsegments:

1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, Luminex xMAP Technology

2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR), Digital PCR (dPCR), Reverse Transcription PCR (RT-PCR)

3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, RNA Sequencing (RNA-Seq)

4) By Microarrays: DNA Microarrays, RNA Microarrays, SNP Arrays

5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH), Chromogenic In-Situ Hybridization (CISH)

Which Trends Are Shaping Growth In The Cancer Profiling Market?

Major companies operating in the cancer profiling market are prioritizing technological advancements, such as simultaneous whole-exome sequencing (WES) and whole-transcriptome sequencing (WTS) assays, to deliver more comprehensive, tissue-sparing, and clinically actionable molecular diagnostics for precision oncology. These assays integrate DNA (exome) and RNA (transcriptome) analysis within a single workflow, enabling the detection of genomic variants (like SNVs, indels, and copy-number alterations) alongside gene expression or fusion events, which differs from traditional NGS tests that require separate assays or limited gene panels. For instance, in November 2024, Caris Life Sciences, a US-based precision medicine company, secured FDA approval for MI Cancer Seek, an NGS in vitro diagnostic that performs WES and WTS concurrently. This assay utilizes total nucleic acid (TNA) sourced from FFPE tumor tissue to detect single-nucleotide variants, insertions or deletions across 228 genes, microsatellite instability (MSI), tumor mutational burden (TMB), and copy-number amplifications specifically in breast cancer. By consolidating DNA and RNA profiling into one test, it conserves tissue, provides clinically actionable companion diagnostic (CDx) indications across multiple tumor types, and expedites therapy selection through a unified genomic blueprint.

Who Are The Well-Known Companies In The Cancer Profiling Market?

Major companies operating in the cancer profiling market are Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., OmniSeq Comprehensive, Resolution Bioscience, OncoCyte Corporation

Get The Full Cancer Profiling Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

Which Region Is The Largest In The Cancer Profiling Market?

North America was the largest region in the cancer profiling market in 2025. The regions covered in the cancer profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cancer Profiling Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

Browse Through More Reports Similar to the Global Cancer Profiling Market 2026, By The Business Research Company

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Cancer Tumor Profiling Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

Cancer Biomarker Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795